BMO Capital on MapLight Therapeutics (MPLT): 'we contest that opportunity remains in schizophrenia with more upside from Alzheimer's psychosis'
Tweet Send to a Friend
BMO Capital analyst Malcolm Hoffman reiterated an Outperform rating and $46.00 price target on MapLight Therapeutics (NASDAQ: MPLT).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
